시장보고서
상품코드
1156748

세계의 이식 진단 시장 : 업계 동향과 예측(-2029년)

Global Transplant Diagnostics Market - Industry Trends and Forecast to 2029

발행일: | 리서치사: Data Bridge Market Research | 페이지 정보: 영문 | 배송안내 : 문의

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 이식 진단 시장 규모는 2022-2029년 예측기간에 6.8%의 CAGR을 기록할 것으로 예측됩니다.

이식 분야의 기술 진보 증가, 세계의 이식 수술 건수 상승 등이 시장 성장의 주요 촉진요인입니다.

세계의 이식 진단(Transplant Diagnostics) 시장에 대해 조사 분석했으며, 시장 개요, 부문별·지역별 시장 분석, 경쟁 분석, 기업 개요 등 체계적인 정보를 제공하고 있습니다.

목차

제1장 서론

제2장 시장 세분화

제3장 주요 요약

  • 역학
  • PESTEL 분석
  • Porter's Five Forces 분석
  • 기술 혁신

제4장 세계의 이식 진단 시장 : 규제

제5장 주요 전략적 이니셔티브

제6장 업계 인사이트

제7장 시장 개요

  • 성장 촉진요인
    • 이식 수술 건수 상승
    • 이식 분야의 기술 진보 증가
    • 의료비 지출 확대
    • 이식전·이식후 크로스 매칭·키메리즘 검사 채용
  • 성장 억제요인
    • 장기 이식의 고액의 비용
    • 장기 이식의 위험과 어려움
  • 기회
    • 시장 기업에 의한 전략적 이니셔티브
    • 공공·민간·정부에 의한 장기 이식에 대한 투자 증대
    • 장기 이식의 중요성에 대한 인식 확산
  • 과제
    • 장기 이식시에 직면하는 윤리적 과제
    • 장기 제공자 부족과 장기 제공자와 장기 연간 필요수의 격차

제8장 세계의 이식 진단 시장 : 제품 종류별

  • 개요
  • 이식 진단 기구
    • 자동 피펫터·디스펜서
    • 자동화 시스템
    • NGS 기기
    • 리더·분석기
    • 이식 진단 키트
    • 기타 키트
  • 이식 진단 소프트웨어
    • DNA 소프트웨어
    • NGS 소프트웨어
    • 데이터 관리 소프트웨어
    • 기타 소프트웨어
  • 이식 진단 시약
    • 단일클론항체
    • 세포독성 컨트롤
    • 인간 혈청
    • 기타 시약

제9장 세계의 이식 진단 시장 : 기술별

  • 개요
  • PCR 기반 분자 어세이
    • 실시간 PCR
    • Sequence-Specific Primer PCR
    • Sequence-Specific Oligonucleotide PCR
    • 제한효소 절편길이 다형성(RFLP)
    • 기타 PCR 기반 분자 어세이
  • 시퀀싱 기반 분자 어세이
    • 생어 시퀀싱
    • 차세대 시퀀싱
    • 기타 시퀀싱 기반 분자 어세이

제10장 세계의 이식 진단 시장 : 이식 종류별

  • 개요
  • 고형 장기 이식
    • 신장 이식
    • 간 이식
    • 심장 이식
    • 폐 이식
    • 췌장 이식
    • 기타 장기 이식
  • 줄기세포 이식
    • 골수 이식(BMT)
    • 말초혈 줄기세포 이식
    • 제대혈 이식
    • 기타 줄기세포 이식
  • 연조직 이식
    • 피부 이식
    • 연골 이식
    • 부신 자가이식
    • 기타 연조직 이식
  • 골수 이식
    • 자가 골수 이식
    • 동종 골수 이식
    • 제대혈 이식
  • 기타

제11장 세계의 이식 진단 시장 : 용도별

  • 개요
  • 진단 용도
    • 이식 진단 기구
    • 이식 진단 소프트웨어
    • 이식 진단 시약
  • 연구 용도
    • 이식 진단 기구
    • 이식 진단 소프트웨어
    • 이식 진단 시약

제12장 세계의 이식 진단 시장 : 최종사용자별

  • 개요
  • 병원·이식 센터
  • 상업 서비스 프로바이더
  • 연구소·학술기관
  • 기타

제13장 세계의 이식 진단 시장 : 유통 채널별

  • 개요
  • 직접 입찰
  • 소매
  • 기타

제14장 세계의 이식 진단 시장 : 지역별

  • 개요
  • 북미
    • 미국
    • 캐나다
    • 멕시코
  • 아시아태평양
    • 중국
    • 일본
    • 한국
    • 인도
    • 호주
    • 싱가포르
    • 태국
    • 말레이시아
    • 인도네시아
    • 필리핀
    • 기타 아시아태평양
  • 유럽
    • 독일
    • 프랑스
    • 영국
    • 이탈리아
    • 러시아
    • 스페인
    • 터키
    • 네덜란드
    • 스위스
    • 벨기에
    • 기타 유럽
  • 남미
    • 브라질
    • 아르헨티나
    • 기타 남미
  • 중동 및 아프리카
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트
    • 이집트
    • 이스라엘
    • 기타 중동 및 아프리카

제15장 세계의 이식 진단 시장 : 기업 상황

  • 기업 점유율 분석 : 세계
  • 기업 점유율 분석 : 북미
  • 기업 점유율 분석 : 유럽
  • 기업 점유율 분석 : 아시아태평양

제16장 SWOT 분석

제17장 기업 개요

  • ABBOTT
  • THERMO FISHER SCIENTIFIC INC.
  • F. HOFFMANN LA ROCHE LTD
  • TAKARA BIO INC.
  • HOLOGIC, INC
  • ADAPTIVE BIOTECHNOLOGIES
  • ALTONA DIAGNOSTICS
  • ARQUER DIAGNOSTICS LTD
  • BAG DIAGNOSTICS GMBH
  • BIOFORTUNA LIMITED
  • BIOMERIEUX
  • BIO-RAD LABORATORIES, INC.
  • BIOTYPE GMBH
  • CAREDX INC.
  • CLONIT SRL
  • DIAGNOSTICA LONGWOOD SL
  • DIASORIN S.P.A.
  • ELITECHGROUP
  • EUROFINS VIRACOR
  • HORIBA LTD
  • ILLUMINA, INC.
  • IMMUCOR
  • LABORATORY CORPORATION OF AMERICA HOLDINGS.
  • LUMINEX CORPORATION.(A SUBSIDIARY OF DIASORIN)
  • NANOSTRING
  • PATHONOSTICS
  • PRESERVATION SOLUTIONS, INC.
  • QIAGEN
  • RANDOX LABORATORIES LTD.
  • STRYKER
  • TRANSMEDICS
  • TRANSONIC.
  • ZIMMER BIOMET

제18장 앙케이트

제19장 관련 보고서

KSM 22.12.05

Global transplant diagnostics market is projected to register a CAGR of 6.8% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2022 to 2029.

Market Segmentation:

Global Transplant Diagnostics Market, By Product Type (Transplant Diagnostic Instrument, Transplant Diagnostic Software, Transplant Diagnostic Reagent), Technology (PCR-Based Molecular Assays, Sequencing-Based Molecular Assays), Transplant Type (Solid Organ Transplantation, Stem Cell Transplantation, Soft Tissue Transplantation, Bone Marrow Transplantation, Other Transplants), Application (Diagnostic Applications, Research Applications), End User (Research Laboratories and Academic Institutes, Hospital and Transplant Centers, Commercial Service Providers, Others), Distribution Channel (Direct Tender, Retail Sales, Others), Country (U.S., Canada, Mexico, Germany, France, the U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, and the Rest of Europe, China, Japan, India, South Korea, Singapore, Thailand, Malaysia, Australia, Philippines, Indonesia, and the Rest of Asia-Pacific, South Africa, Saudi Arabia, UAE, Egypt, Israel, and the Rest of the Middle East and Africa) Industry Trends and Forecast to 2029.

Some of the major factors contributing to the growth of the global transplant diagnostics market are:

Increase in the technological advancements in the field of transplant

Rising number of transplant procedures globally

Market Players:

Some of the major players operating in the global transplant diagnostics market are:

Hologic, Inc.

Biofortuna Limited

Takara Bio Inc.

Abbott

Diagnostica Longwood SL

Adaptive Biotechnologies

NanoString

Arquer Diagnostics Ltd

altona Diagnostics GmbH

ELITechGroup

DiaSorin S.p.A.

Horiba Ltd

EUROFINS VIRACOR

CareDx Inc.

Laboratory Corporation of America Holdings.

Randox Laboratories Ltd.

Thermo Fisher Scientific Inc.

Preservation Solutions, Inc.

TransMedics

Transonic

Stryker

Bio-Rad Laboratories, Inc.

Zimmer Biomet

QIAGEN

F. Hoffmann-La Roche Ltd

BIOMERIEUX

Illumina, Inc.

Luminex Corporation (A subsidiary of DiaSorin Company)

IMMUCOR

CLONIT srl

PathoNostics

Biotype GmbH

BAG Diagnostics GmbH

TABLE OF CONTENTS

1 INTRODUCTION 75

  • 1.1 OBJECTIVES OF THE STUDY 75
  • 1.2 MARKET DEFINITION 75
  • 1.3 OVERVIEW OF THE GLOBAL TRANSPLANT DIAGNOSTICS MARKET 75
  • 1.4 CURRENCY AND PRICING 78
  • 1.5 LIMITATIONS 78
  • 1.6 MARKETS COVERED 78

2 MARKET SEGMENTATION 84

  • 2.1 MARKETS COVERED 84
  • 2.2 GEOGRAPHICAL SCOPE 85
  • 2.3 YEARS CONSIDERED FOR THE STUDY 86
  • 2.4 DBMR TRIPOD DATA VALIDATION MODEL 87
  • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 90
  • 2.6 MULTIVARIATE MODELLING 91
  • 2.7 MARKET APPLICATION COVERAGE GRID 92
  • 2.8 SOURCE LIFELINE CURVE 93
  • 2.9 DBMR MARKET POSITION GRID 94
  • 2.10 VENDOR SHARE ANALYSIS 95
  • 2.11 SECONDARY SOURCES 96
  • 2.12 ASSUMPTIONS 96

3 EXECUTIVE SUMMARY 97

  • 3.1 EPIDEMOLOGY 103
  • 3.2 PESTEL_ANALYSIS 118
  • 3.3 PORTER'S FIVE FORCE 119
  • 3.4 TECHNOLOGICAL INNOVATIONS 120

4 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: REGULATIONS 121

5 KEY STRATEGIC INITIATIVES 125

6 INDUSTRIAL INSIGHTS: 126

7 MARKET OVERVIEW 128

  • 7.1 DRIVERS 130
    • 7.1.1 RISING NUMBER OF TRANSPLANT PROCEDURES 130
    • 7.1.2 INCREASE IN THE TECHNOLOGICAL ADVANCEMENTS IN THE FIELD OF TRANSPLANTS 130
    • 7.1.3 RISING HEALTHCARE SPENDING 130
    • 7.1.4 ADOPTION OF CROSS-MATCHING AND CHIMERISM TESTING DURING PRE- AND POST-TRANSPLANTATION 131
  • 7.2 RESTRAINTS 131
    • 7.2.1 HIGH COST OF ORGAN TRANSPLANTATION 131
    • 7.2.2 THE RISKS AND DIFFICULTIES OF ORGAN TRANSPLANTATION 131
  • 7.3 OPPORTUNITIES 132
    • 7.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS 132
    • 7.3.2 RISE IN PUBLIC, PRIVATE, AND GOVERNMENT FUNDING FOR ORGAN TRANSPLANTATION 132
    • 7.3.3 SURGE IN AWARENESS ABOUT THE IMPORTANCE OF ORGAN TRANSPLANTATION 133
  • 7.4 CHALLENGES 134
    • 7.4.1 ETHICAL CHALLENGES FACED DURING ORGAN TRANSPLANTATION 134
    • 7.4.2 LACK OF ORGAN DONORS OR GAP BETWEEN ORGAN DONORS AND ORGANS NEEDED ANNUALLY 134

8 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE 136

  • 8.1 OVERVIEW 137
  • 8.2 TRANSPLANT DIAGNOSTIC INSTRUMENTS 140
    • 8.2.1 AUTOMATED PIPETTORS & DISPENSERS 140
    • 8.2.2 AUTOMATED SYSTEMS 140
      • 8.2.2.1 NUCLEIC ACID EXTRACTION SYSTEM 141
      • 8.2.2.2 PCR SETUP 141
      • 8.2.2.3 OTHERS 141
    • 8.2.3 NGS INSTRUMENTS 141
    • 8.2.4 READERS & ANALYZERS 141
    • 8.2.5 TRANSPLANT DIAGNOSTIC KITS 141
      • 8.2.5.1 ASPERGILLUS SPP KITS 142
      • 8.2.5.2 P. JIROVECII KITS 142
      • 8.2.5.3 CMV KITS 142
      • 8.2.5.4 EBV KITS 142
      • 8.2.5.5 BKV KITS 143
      • 8.2.5.6 VZV KITS 143
      • 8.2.5.7 HSV1 KITS 143
      • 8.2.5.8 HSV2 KITS 143
      • 8.2.5.9 PARVOVIRUS B19 KITS 143
      • 8.2.5.10 ADENOVIRUS KITS 143
      • 8.2.5.11 ENTEROVIRUS KITS 143
      • 8.2.5.12 JCV KITS 143
      • 8.2.5.13 HHV6 KITS 143
      • 8.2.5.14 HHV7 KITS 143
      • 8.2.5.15 HHV8 KITS 143
      • 8.2.5.16 TOXOPLASMA GONDII KITS 143
      • 8.2.5.17 HEPATITIS E KITS 144
      • 8.2.5.18 OTHER KITS 144
    • 8.2.6 OTHER KITS 144
  • 8.3 TRANSPLANT DIAGNOSTIC SOFTWARE'S 144
    • 8.3.1 DNA SOFTWARE 145
    • 8.3.2 NGS SOFTWARE 145
    • 8.3.3 DATA MANAGEMENT SOFTWARE 145
    • 8.3.4 OTHER SOFTWARE'S 145
  • 8.4 TRANSPLANT DIAGNOSTIC REAGENTS 145
    • 8.4.1 MONOCLONAL ANTIBODIES 146
    • 8.4.2 CYTOTOXIC CONTROLS 146
    • 8.4.3 HUMAN SERUM 146
    • 8.4.4 OTHER REAGENTS 146

9 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY 147

  • 9.1 OVERVIEW 148
  • 9.2 PCR-BASED MOLECULAR ASSAYS 151
    • 9.2.1 REAL TIME PCR 151
    • 9.2.2 SEQUENCE-SPECIFIC PRIMER-PCR 151
    • 9.2.3 SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR 152
    • 9.2.4 RESTRICTION FRAGMENT LENGTH POLYMORPHISM (RFLP) 152
    • 9.2.5 OTHER-PCR BASED MOLECULAR ASSAYS 152
  • 9.3 SEQUENCING-BASED MOLECULAR ASSAYS 152
    • 9.3.1 SANGER SEQUENCING 153
    • 9.3.2 NEXT GENERATION SEQUENCING 153
    • 9.3.3 OTHER SEQUENCING-BASED MOLECULAR ASSAYS. 153

10 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE 154

  • 10.1 OVERVIEW 155
  • 10.2 SOLID ORGAN TRANSPLANTATION 158
    • 10.2.1 KIDNEY TRANSPLANTATION 158
    • 10.2.2 LIVER TRANSPLANTATION 158
    • 10.2.3 HEART TRANSPLANTATION 159
    • 10.2.4 LUNG TRANSPLANTATION 159
    • 10.2.5 PANCREAS TRANSPLANTATION 159
    • 10.2.6 OTHER ORGAN TRANSPLANTATIONS 159
  • 10.3 STEM CELL TRANSPLANTATION 159
    • 10.3.1 BONE MARROW TRANSPLANT (BMT) 160
    • 10.3.2 PERIPHERAL BLOOD STEM CELL TRANSPLANT 160
    • 10.3.3 CORD BLOOD TRANSPLANT 160
    • 10.3.4 OTHER STEM CELL TRANSPLANTS 160
  • 10.4 SOFT TISSUE TRANSPLANTATION 160
    • 10.4.1 SKIN GRAFT 161
    • 10.4.2 CARTILAGE TRANSPLANTATION 161
    • 10.4.3 ADRENAL AUTOGRAFTING 161
    • 10.4.4 OTHER SOFT TISSUE TRANSPLANTATION. 161
  • 10.5 BONE MARROW TRANSPLANTATION 162
    • 10.5.1 AUTOLOGOUS BONE MARROW TRANSPLANT 162
    • 10.5.2 ALLOGENEIC BONE MARROW TRANSPLANT 162
    • 10.5.3 UMBILICAL CORD BLOOD TRANSPLANT. 163
  • 10.6 OTHERS 163

11 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION 164

  • 11.1 OVERVIEW 165
  • 11.2 DIAGNOSTIC APPLICATIONS 168
    • 11.2.1 TRANSPLANT DIAGNOSTIC INSTRUMENT 168
      • 11.2.1.1 AUTOMATED PIPETTORS & DISPENSERS 169
      • 11.2.1.2 AUTOMATED SYSTEMS 169
      • 11.2.1.3 NGS INSTRUMENTS 169
      • 11.2.1.4 READERS & ANALYZERS 169
      • 11.2.1.5 TRANSPLANT DIAGNOSTIC KITS 169
      • 11.2.1.6 OTHERS 169
    • 11.2.2 TRANSPLANT DIAGNOSTIC SOFTWARE 169
      • 11.2.2.1 DNA SOFTWARE 170
      • 11.2.2.2 NGS SOFTWARE 170
      • 11.2.2.3 DATA MANAGEMENT SOFTWARE 170
      • 11.2.2.4 OTHER SOFTWARES 170
    • 11.2.3 TRANSPLANT DIAGNOSTIC REAGENT 170
      • 11.2.3.1 MONOCLONAL ANTIBODIES 171
      • 11.2.3.2 CYTOTOXIC CONTROLS 171
      • 11.2.3.3 HUMAN SERUM 171
      • 11.2.3.4 OTHER REAGENTS 171
  • 11.3 RESEARCH APPLICATIONS 171
    • 11.3.1 TRANSPLANT DIAGNOSTIC INSTRUMENT 172
      • 11.3.1.1 AUTOMATED PIPETTORS & DISPENSERS 173
      • 11.3.1.2 AUTOMATED SYSTEMS 173
      • 11.3.1.3 NGS INSTRUMENTS 173
      • 11.3.1.4 READERS & ANALYZERS 173
      • 11.3.1.5 TRANSPLANT DIAGNOSTIC KITS 173
      • 11.3.1.6 OTHERS 173
    • 11.3.2 TRANSPLANT DIAGNOSTIC SOFTWARE 173
      • 11.3.2.1 DNA SOFTWARE 174
      • 11.3.2.2 NGS SOFTWARE 174
      • 11.3.2.3 DATA MANAGEMENT SOFTWARE 174
      • 11.3.2.4 OTHER SOFTWARES 174
    • 11.3.3 TRANSPLANT DIAGNOSTIC REAGENT 174
      • 11.3.3.1 MONOCLONAL ANTIBODIES 175
      • 11.3.3.2 CYTOTOXIC CONTROLS 175
      • 11.3.3.3 HUMAN SERUM 175
      • 11.3.3.4 OTHER REAGENTS 175

12 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY END USER 176

  • 12.1 OVERVIEW 177
  • 12.2 HOSPITALS AND TRANSPLANT CENTERS 180
  • 12.3 COMMERCIAL SERVICE PROVIDERS 180
  • 12.4 RESEARCH LABORATORIES AND ACADEMIC INSTITUTES 180
  • 12.5 OTHERS 181

13 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 182

  • 13.1 OVERVIEW 183
  • 13.2 DIRECT TENDER 186
  • 13.3 RETAIL SALES 186
  • 13.4 OTHERS 186

14 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY REGION 188

  • 14.1 OVERVIEW 189
  • 14.2 NORTH AMERICA 194
    • 14.2.1 U.S. 206
    • 14.2.2 CANADA 218
    • 14.2.3 MEXICO 230
  • 14.3 ASIA-PACIFIC 242
    • 14.3.1 CHINA 256
    • 14.3.2 JAPAN 268
    • 14.3.3 SOUTH KOREA 280
    • 14.3.4 INDIA 292
    • 14.3.5 AUSTRALIA 304
    • 14.3.6 SINGAPORE 316
    • 14.3.7 THAILAND 328
    • 14.3.8 MALAYSIA 340
    • 14.3.9 INDONESIA 352
    • 14.3.10 PHILIPPINES 364
    • 14.3.11 REST OF ASIA-PACIFIC 376
  • 14.4 EUROPE 377
    • 14.4.1 GERMANY 392
    • 14.4.2 FRANCE 404
    • 14.4.3 U.K. 416
    • 14.4.4 ITALY 428
    • 14.4.5 RUSSIA 440
    • 14.4.6 SPAIN 452
    • 14.4.7 TURKEY 464
    • 14.4.8 NETHERLANDS 476
    • 14.4.9 SWITZERLAND 488
    • 14.4.10 BELGIUM 500
    • 14.4.11 REST OF EUROPE 512
  • 14.5 SOUTH AMERICA 513
    • 14.5.1 BRAZIL 525
    • 14.5.2 ARGENTINA 537
    • 14.5.3 REST OF SOUTH AMERICA 549
  • 14.6 MIDDLE EAST & AFRICA 550
    • 14.6.1 SOUTH AFRICA 563
    • 14.6.2 SAUDI ARABIA 575
    • 14.6.3 U.A.E 587
    • 14.6.4 EGYPT 599
    • 14.6.5 ISRAEL 611
    • 14.6.6 REST OF MIDDLE EAST AND AFRICA 623

15 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: COMPANY LANDSCAPE 624

  • 15.1 COMPANY SHARE ANALYSIS: GLOBAL 624
  • 15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 625
  • 15.3 COMPANY SHARE ANALYSIS: EUROPE 626
  • 15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 627

16 SWOT ANALYSIS 628

17 COMPANY PROFILE 629

  • 17.1 ABBOTT 629
    • 17.1.1 COMPANY SNAPSHOT 629
    • 17.1.2 REVENUE ANALYSIS 629
    • 17.1.3 COMPANY SHARE ANALYSIS 630
    • 17.1.4 PRODUCT PORTFOLIO 630
    • 17.1.5 RECENT DEVELOPMENTS 630
  • 17.2 THERMO FISHER SCIENTIFIC INC. 631
    • 17.2.1 COMPANY SNAPSHOT 631
    • 17.2.2 REVENUE ANALYSIS 631
    • 17.2.3 COMPANY SHARE ANALYSIS 632
    • 17.2.4 PRODUCT PORTFOLIO 632
    • 17.2.5 RECENT DEVELOPMENTS 634
  • 17.3 F. HOFFMANN LA ROCHE LTD 635
    • 17.3.1 COMPANY SNAPSHOT 635
    • 17.3.2 REVENUE ANALYSIS 635
    • 17.3.3 COMPANY SHARE ANALYSIS 636
    • 17.3.4 PRODUCT PORTFOLIO 636
    • 17.3.5 RECENT DEVELOPMENT 637
  • 17.4 TAKARA BIO INC. 638
    • 17.4.1 COMPANY SNAPSHOT 638
    • 17.4.2 REVENUE ANALYSIS 638
    • 17.4.3 COMPANY SHARE ANALYSIS 639
    • 17.4.4 PRODUCT PORTFOLIO 639
    • 17.4.5 RECENT DEVELOPMENTS 639
  • 17.5 HOLOGIC, INC 640
    • 17.5.1 COMPANY SNAPSHOT 640
    • 17.5.2 REVENUE ANALYSIS 640
    • 17.5.3 COMPANY SHARE ANALYSIS 641
    • 17.5.4 PRODUCT PORTFOLIO 641
    • 17.5.5 RECENT DEVELOPMENTS 642
  • 17.6 ADAPTIVE BIOTECHNOLOGIES 643
    • 17.6.1 COMPANY SNAPSHOT 643
    • 17.6.2 REVENUE ANALYSIS 643
    • 17.6.3 PRODUCT PORTFOLIO 644
    • 17.6.4 RECENT DEVELOPMENT 644
  • 17.7 ALTONA DIAGNOSTICS 645
    • 17.7.1 COMPANY SNAPSHOT 645
    • 17.7.2 PRODUCT PORTFOLIO 645
    • 17.7.3 RECENT DEVELOPMENTS 645
  • 17.8 ARQUER DIAGNOSTICS LTD 646
    • 17.8.1 COMPANY SNAPSHOT 646
    • 17.8.2 PRODUCT PORTFOLIO 646
    • 17.8.3 RECENT DEVELOPMENTS 647
  • 17.9 BAG DIAGNOSTICS GMBH 648
    • 17.9.1 COMPANY SNAPSHOT 648
    • 17.9.2 PRODUCT PORTFOLIO 648
    • 17.9.3 RECENT DEVELOPMENTS 648
  • 17.10 BIOFORTUNA LIMITED 649
    • 17.10.1 COMPANY SNAPSHOT 649
    • 17.10.2 PRODUCT PORTFOLIO 649
    • 17.10.3 RECENT DEVELOPMENT 649
  • 17.11 BIOMERIEUX 650
    • 17.11.1 COMPANY SNAPSHOT 650
    • 17.11.2 REVENUE ANALYSIS 650
    • 17.11.3 PRODUCT PORTFOLIO 651
    • 17.11.4 RECENT DEVELOPMENTS 651
  • 17.12 BIO-RAD LABORATORIES, INC. 652
    • 17.12.1 COMPANY SNAPSHOT 652
    • 17.12.2 REVENUE ANALYSIS 652
    • 17.12.3 PRODUCT PORTFOLIO 653
    • 17.12.4 RECENT DEVELOPMENT 654
  • 17.13 BIOTYPE GMBH 655
    • 17.13.1 COMPANY SNAPSHOT 655
    • 17.13.2 PRODUCT PORTFOLIO 655
    • 17.13.3 RECENT DEVELOPMENTS 656
  • 17.14 CAREDX INC. 657
    • 17.14.1 COMPANY SNAPSHOT 657
    • 17.14.2 REVENUE ANALYSIS 657
    • 17.14.3 PRODUCT PORTFOLIO 658
    • 17.14.4 RECENT DEVELOPMENTS 660
  • 17.15 CLONIT SRL 661
    • 17.15.1 COMPANY SNAPSHOT 661
    • 17.15.2 PRODUCT PORTFOLIO 661
    • 17.15.3 RECENT DEVELOPMENT 663
  • 17.16 DIAGNOSTICA LONGWOOD SL 664
    • 17.16.1 COMPANY SNAPSHOT 664
    • 17.16.2 PRODUCT PORTFOLIO 664
    • 17.16.3 RECENT DEVELOPMENTS 664
  • 17.17 DIASORIN S.P.A. 665
    • 17.17.1 COMPANY SNAPSHOT 665
    • 17.17.2 REVENUE ANALYSIS 665
    • 17.17.3 PRODUCT PORTFOLIO 666
    • 17.17.4 RECENT DEVELOPMENT 666
  • 17.18 ELITECHGROUP 667
    • 17.18.1 COMPANY SNAPSHOT 667
    • 17.18.2 PRODUCT PORTFOLIO 667
    • 17.18.3 RECENT DEVELOPMENTS 667
  • 17.19 EUROFINS VIRACOR 668
    • 17.19.1 COMPANY SNAPSHOT 668
    • 17.19.2 PRODUCT PORTFOLIO 668
    • 17.19.3 RECENT DEVELOPMENTS 669
  • 17.20 HORIBA LTD 670
    • 17.20.1 COMPANY SNAPSHOT 670
    • 17.20.2 REVENUE ANALYSIS 670
    • 17.20.3 PRODUCT PORTFOLIO 671
    • 17.20.4 RECENT DEVELOPMENT 671
  • 17.21 ILLUMINA, INC. 672
    • 17.21.1 COMPANY SNAPSHOT 672
    • 17.21.2 REVENUE ANALYSIS 672
    • 17.21.3 PRODUCT PORTFOLIO 673
    • 17.21.4 RECENT DEVELOPMENTS 673
  • 17.22 IMMUCOR 674
    • 17.22.1 COMPANY SNAPSHOT 674
    • 17.22.2 PRODUCT PORTFOLIO 674
    • 17.22.3 RECENT DEVELOPMENTS 674
  • 17.23 LABORATORY CORPORATION OF AMERICA HOLDINGS. 675
    • 17.23.1 COMPANY SNAPSHOT 675
    • 17.23.2 REVENUE ANALYSIS 675
    • 17.23.3 PRODUCT PORTFOLIO 676
    • 17.23.4 RECENT DEVELOPMENTS 677
  • 17.24 LUMINEX CORPORATION. (A SUBSIDIARY OF DIASORIN) 678
    • 17.24.1 COMPANY SNAPSHOT 678
    • 17.24.2 REVENUE ANALYSIS 678
    • 17.24.3 PRODUCT PORTFOLIO 679
    • 17.24.4 RECENT DEVELOPMENT 679
  • 17.25 NANOSTRING 680
    • 17.25.1 COMPANY SNAPSHOT 680
    • 17.25.2 REVENUE ANALYSIS 680
    • 17.25.3 PRODUCT PORTFOLIO 681
    • 17.25.4 RECENT DEVELOPMENT 681
  • 17.26 PATHONOSTICS 682
    • 17.26.1 COMPANY SNAPSHOT 682
    • 17.26.2 PRODUCT PORTFOLIO 682
    • 17.26.3 RECENT DEVELOPMENTS 682
  • 17.27 PRESERVATION SOLUTIONS, INC. 683
    • 17.27.1 COMPANY SNAPSHOT 683
    • 17.27.2 PRODUCT PORTFOLIO 683
    • 17.27.3 RECENT DEVELOPMENTS 683
  • 17.28 QIAGEN 684
    • 17.28.1 COMPANY SNAPSHOT 684
    • 17.28.2 REVENUE ANALYSIS 684
    • 17.28.3 PRODUCT PORTFOLIO 685
    • 17.28.4 RECENT DEVELOPMENTS 686
  • 17.29 RANDOX LABORATORIES LTD. 687
    • 17.29.1 COMPANY SNAPSHOT 687
    • 17.29.2 PRODUCT PORTFOLIO 687
    • 17.29.3 RECENT DEVELOPMENTS 688
  • 17.30 STRYKER 689
    • 17.30.1 COMPANY SNAPSHOT 689
    • 17.30.2 REVENUE ANALYSIS 689
    • 17.30.3 PRODUCT PORTFOLIO 690
    • 17.30.4 RECENT DEVELOPMENT 690
  • 17.31 TRANSMEDICS 691
    • 17.31.1 COMPANY SNAPSHOT 691
    • 17.31.2 REVENUE ANALYSIS 691
    • 17.31.3 PRODUCT PORTFOLIO 692
    • 17.31.4 RECENT DEVELOPMENTS 692
  • 17.32 TRANSONIC. 693
    • 17.32.1 COMPANY SNAPSHOT 693
    • 17.32.2 PRODUCT PORTFOLIO 693
    • 17.32.3 RECENT DEVELOPMENT 693
  • 17.33 ZIMMER BIOMET 694
    • 17.33.1 COMPANY SNAPSHOT 694
    • 17.33.2 REVENUE ANALYSIS 694
    • 17.33.3 PRODUCT PORTFOLIO 695
    • 17.33.4 RECENT DEVELOPMENTS 695

18 QUESTIONNAIRE 696

19 RELATED REPORTS 699

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제